Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

ZORBTIVE

SOMATROPIN RECOMBINANT

Standard Dose
4MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ZORBTIVE is listed in Drugs@FDA under application 021597 (BLA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SOMATROPIN RECOMBINANT Form and strength INJECTABLE;INJECTION - 4MG/VIAL Sponsor EMD SERONO Submission history Latest submission status date: 2003-12-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZORBTIVE is listed in Drugs@FDA under application 021597 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SOMATROPIN RECOMBINANT Form and strength INJECTABLE;INJECTION - 4MG/VIAL Sponsor EMD SERONO Submission history Latest submission status date: 2003-12-01 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.